Profile data is unavailable for this security.
About the company
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
- Revenue in USD (TTM)81.33bn
- Net income in USD16.33bn
- Incorporated1887
- Employees135.10k
- LocationJohnson & Johnson1 Johnson And Johnson PlzNEW BRUNSWICK 08933-0001United StatesUSA
- Phone+1 (732) 524-2455
- Fax+1 (732) 214-0332
- Websitehttps://www.jnj.com/
Mergers & acquisitions
| Acquired company | JNJ:NYQ since announced | Transaction value |
|---|---|---|
| Innovalens BV | -1.82% | -- |
| CIC Corp | -4.92% | 711.33m |
| Ci:z Holdings Co Ltd | -4.92% | 1.33bn |
| EIT Emerging Implant Technologies GmbH | -2.29% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Co | 23.29bn | 5.17bn | 72.18bn | 23.30k | 13.97 | 4.74 | 12.19 | 3.10 | 3.16 | 3.14 | 14.23 | 9.30 | 0.6858 | 5.35 | 5.19 | 999,485.00 | 15.29 | 10.05 | 21.08 | 13.92 | 71.13 | 73.87 | 22.29 | 17.90 | 1.79 | 28.85 | 0.282 | 74.94 | 8.59 | 6.61 | 27.49 | 14.19 | 12.11 | 2.71 |
| Gilead Sciences, Inc. | 22.32bn | 5.90bn | 85.09bn | 11.00k | 14.75 | 3.88 | 11.62 | 3.81 | 4.54 | 4.54 | 17.20 | 17.23 | 0.3482 | 5.39 | 6.32 | 2,029,091.00 | 9.19 | 23.08 | 10.92 | 28.22 | 78.45 | 84.37 | 26.40 | 43.52 | 3.53 | 10.79 | 0.5461 | 17.01 | -15.24 | 14.59 | -46.06 | 12.17 | 37.10 | -- |
| AbbVie Inc | 32.65bn | 5.42bn | 101.00bn | 30.00k | 19.32 | -- | 13.88 | 3.09 | 3.54 | 3.48 | 21.58 | -5.29 | 0.5178 | 4.31 | 5.67 | 1,088,233.00 | 8.64 | 9.30 | 11.45 | 12.12 | 77.31 | 77.24 | 16.68 | 18.82 | 0.9142 | 5.26 | 1.27 | 83.76 | 16.08 | 11.75 | 1.06 | 6.83 | 5.38 | 17.54 |
| Eli Lilly And Co | 23.95bn | 2.75bn | 103.97bn | 38.68k | 39.50 | 41.92 | 24.23 | 4.34 | 2.71 | 6.28 | 23.58 | 2.55 | 0.5815 | 1.56 | 4.95 | 619,128.80 | 6.68 | 6.48 | 9.26 | 9.00 | 74.96 | 74.01 | 11.49 | 11.69 | 0.8493 | 29.72 | 0.8616 | 87.08 | 7.36 | 1.22 | 99.27 | -6.17 | 22.52 | 2.80 |
| Amgen, Inc. | 23.75bn | 8.08bn | 108.00bn | 21.50k | 14.13 | 10.04 | 10.75 | 4.55 | 12.53 | 12.53 | 36.88 | 17.63 | 0.3514 | 1.41 | 6.42 | 1,104,651.00 | 11.95 | 9.96 | 14.42 | 11.42 | 82.27 | 81.15 | 34.00 | 32.60 | 2.53 | 13.02 | 0.753 | 40.32 | 3.93 | 4.92 | 3.90 | 10.56 | 1.27 | 22.94 |
| Merck & Co., Inc. | 43.07bn | 8.76bn | 210.91bn | 69.00k | 24.75 | 7.68 | 16.29 | 4.90 | 3.31 | 3.17 | 16.24 | 10.66 | 0.5116 | 2.40 | 5.80 | 624,246.40 | 10.30 | 6.68 | 13.08 | 8.35 | 69.06 | 66.21 | 20.13 | 15.62 | 1.06 | 42.45 | 0.4834 | 81.41 | 5.41 | -0.8026 | 29.69 | 8.13 | 11.06 | 2.96 |
| Pfizer Inc. | 53.86bn | 10.67bn | 237.63bn | 92.40k | 23.67 | 4.04 | 13.93 | 4.41 | 1.81 | 1.95 | 9.18 | 10.58 | 0.3366 | 1.36 | 5.65 | 582,889.60 | 6.69 | 5.41 | 8.15 | 6.50 | 79.57 | 79.42 | 19.87 | 17.73 | 1.27 | 31.44 | 0.4328 | 81.63 | 2.10 | 0.7874 | -13.10 | -1.88 | 8.43 | 7.21 |
| Johnson & Johnson | 81.33bn | 16.33bn | 350.10bn | 135.10k | 21.87 | -- | 21.95 | 4.30 | 6.03 | 6.03 | 30.00 | -- | -- | -- | -- | 601,961.50 | -- | 11.03 | -- | 13.72 | 66.81 | 68.43 | 20.08 | 20.80 | -- | 199.64 | -- | 55.22 | 6.71 | 2.73 | 6.97 | 2.04 | 0.4138 | 6.45 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2019 | 219.81m | 8.28% |
| SSgA Funds Management, Inc.as of 31 Mar 2019 | 155.14m | 5.84% |
| BlackRock Fund Advisorsas of 31 Mar 2019 | 128.54m | 4.84% |
| State Farm Investment Management Corp.as of 31 Mar 2019 | 37.88m | 1.43% |
| Geode Capital Management LLCas of 31 Mar 2019 | 35.84m | 1.35% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2019 | 34.94m | 1.32% |
| Massachusetts Financial Services Co.as of 31 Mar 2019 | 28.15m | 1.06% |
| Norges Bank Investment Managementas of 31 Dec 2018 | 27.01m | 1.02% |
| Wellington Management Co. LLPas of 31 Mar 2019 | 23.90m | 0.90% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2019 | 22.61m | 0.85% |
